Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT05431582 Withdrawn - Breast Cancer Clinical Trials

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Start date: December 14, 2022
Phase: Phase 1
Study type: Interventional

Primary Objectives are to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of ZN-c3 and ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors as well to evaluate antitumor activity of ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors.

NCT ID: NCT05431530 Recruiting - Quality of Life Clinical Trials

Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer

LAPSODY
Start date: June 22, 2022
Phase:
Study type: Observational

This study aims to evaluate the incidence of low anterior resection syndrome and quality of life after cytoreductive surgery for advanced ovarian cancer patients.

NCT ID: NCT05430906 Recruiting - Ovarian Cancer Clinical Trials

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

Start date: November 25, 2022
Phase: Phase 2
Study type: Interventional

Previous studies have suggested that immunotherapy combined with chemotherapy as neoadjuvant treatment for ovarian cancer may have a synergistic effect and a manageable safety profile. AK104 is a bispecific antibody targeting PD-1 and CTLA-4. Therefore, this study aimed to evaluate the efficacy and safety of AK104 combined with chemotherapy as the neoadjuvant treatment for advanced ovarian cancer.

NCT ID: NCT05429970 Recruiting - Ovarian Cancer Clinical Trials

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Start date: June 17, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery/PDS or IDS and also if it's better than the standard-of-care approach (no intervention for reducing stress).

NCT ID: NCT05427487 Recruiting - Colorectal Cancer Clinical Trials

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Start date: February 17, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in people with micro satellite-stable (MSS) colorectal or gastroesophageal cancer metastatic to liver, or advanced ovarian cancer.

NCT ID: NCT05427214 Recruiting - Lung Cancer Clinical Trials

Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy

Dragon
Start date: August 19, 2022
Phase: N/A
Study type: Interventional

This prospective imaging study is evaluating the feasibility of using the Halcyon 4.0 radiotherapy system for radiation therapy planning in patients with cancer. The Halcyon 4.0 system has been engineered to decrease the image acquisition time and the radiation exposure, but the system has not yet been clinically validated for use in radiation planning. This pilot study will evaluate images obtained on the Halcyon 4.0 system to assess if the quality is sufficient for radiation treatment plan construction.

NCT ID: NCT05422183 Not yet recruiting - Clinical trials for Ovarian Cancer, Epithelial

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Start date: June 30, 2022
Phase: Phase 2
Study type: Interventional

This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian cancer,primary fallopian tube cancer and primary peritoneal carcinoma.

NCT ID: NCT05420545 Recruiting - Ovarian Cancer Clinical Trials

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Start date: December 31, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.

NCT ID: NCT05415527 Recruiting - Ovarian Carcinoma Clinical Trials

Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management

OPTIMOVA
Start date: June 11, 2022
Phase: N/A
Study type: Interventional

Prospective, monocentric study evaluating the presence of sarcopenia prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management.

NCT ID: NCT05415098 Recruiting - Gastric Cancer Clinical Trials

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Start date: September 30, 2022
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally. Patients will be treated in 28-day cycles.